GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons

被引:217
作者
Cole, AR
Knebel, A
Morrice, NA
Robertson, LA
Irving, AJ
Connolly, CN
Sutherland, C [1 ]
机构
[1] Univ Dundee, Ninewells Hosp, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland
[2] Univ Dundee, Sch Life Sci, Lab 4 21, Kinasource, Dundee DD1 4HN, Scotland
[3] Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland
基金
英国生物技术与生命科学研究理事会;
关键词
D O I
10.1074/jbc.C400412200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Elevated glycogen synthase kinase-3 (GSK-3) activity is associated with Alzheimer disease. We have found that collapsin response mediator proteins (CRMP) 2 and 4 are physiological substrates of GSK-3. The amino acids targeted by GSK-3 comprise a hyperphosphorylated epitope first identified in plaques isolated from Alzheimer brain. Expression of wild type CRMP2 in primary hippocampal neurons or SH-SY5Y neuroblastoma cells promotes axon elongation. However, a GSK-3-insensitive CRMP2 mutant has dramatically reduced ability to promote axon elongation, a similar effect to pharmacological inhibition of GSK-3. Hence, we propose that phosphorylation of CRMP proteins by GSK-3 regulates axon elongation. This work provides a direct connection between hyperphosphorylation of these residues and elevated GSK-3 activity, both of which are observed in Alzheimer brain.
引用
收藏
页码:50176 / 50180
页数:5
相关论文
共 31 条
  • [1] Role of CRMP-2 in neuronal polarity
    Arimura, N
    Menager, C
    Fukata, Y
    Kaibuchi, K
    [J]. JOURNAL OF NEUROBIOLOGY, 2004, 58 (01): : 34 - 47
  • [2] Campbell David G, 2002, J Biomol Tech, V13, P119
  • [3] Collapsin response mediator proteins (CRMPs) - Involvement in nervoust system development and adult neurodegenerative disorders
    Charrier, E
    Reibel, S
    Rogemond, V
    Aguera, M
    Thomasset, N
    Honnorat, J
    [J]. MOLECULAR NEUROBIOLOGY, 2003, 28 (01) : 51 - 63
  • [4] GSK3 inhibitors: Development and therapeutic potential
    Cohen, P
    Goedert, M
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (06) : 479 - 487
  • [5] Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event
    Cole, A
    Frame, S
    Cohen, P
    [J]. BIOCHEMICAL JOURNAL, 2004, 377 : 249 - 255
  • [6] Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death
    Cross, DAE
    Culbert, AA
    Chalmers, KA
    Facci, L
    Skaper, SD
    Reith, AD
    [J]. JOURNAL OF NEUROCHEMISTRY, 2001, 77 (01) : 94 - 102
  • [7] GSK-3: tricks of the trade for a multi-tasking kinase
    Doble, BW
    Woodgett, JR
    [J]. JOURNAL OF CELL SCIENCE, 2003, 116 (07) : 1175 - 1186
  • [8] A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation
    Frame, S
    Cohen, P
    Biondi, RM
    [J]. MOLECULAR CELL, 2001, 7 (06) : 1321 - 1327
  • [9] GSK3 takes centre stage more than 20 years after its discovery
    Frame, S
    Cohen, P
    [J]. BIOCHEMICAL JOURNAL, 2001, 359 (01) : 1 - 16
  • [10] Axon specification in hippocampal neurons
    Fukata, Y
    Kimura, T
    Kaibuchi, K
    [J]. NEUROSCIENCE RESEARCH, 2002, 43 (04) : 305 - 315